Kymera Therapeutics, Inc.
KYMR
Rang in Aktien
#2299
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Aktienkurs
$105.36
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$8.67B
Veränderung (1 Tag)
-2.57%
Veränderung (1 Jahr)
76.10%
Land
US
Handel Kymera Therapeutics, Inc. (KYMR)
Kategorie
Healthcare
EPS für Kymera Therapeutics, Inc. (KYMR)
EPS zum June 2026 TTM: $-3.25
Laut den aktuellen Finanzberichten und dem Aktienkurs von Kymera Therapeutics, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-3.25. Am Ende des Jahres 2023 betrug das EPS $-2.52 ein Rückgang im Vergleich zu dem EPS von 2022, das $-2.87 betrug.
EPS-Verlauf von Kymera Therapeutics, Inc. von 2018 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-3.25 | 9.06% |
| 2024 | $-2.98 | 18.25% |
| 2023 | $-2.52 | -12.20% |
| 2022 | $-2.87 | 37.32% |
| 2021 | $-2.09 | 111.11% |
| 2020 | $-0.99 | 6.45% |
| 2019 | $-0.93 | 93.75% |
| 2018 | $-0.48 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -632.92% |
US
|
|
| $-7.98 | 145.54% |
US
|
|
| $-5.29 | 62.77% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -953.54% |
NL
|
